Takeda’s recently announced reorganization may affect approximately 634 U.S. employees, including 247 in Cambridge, Massachusetts effective July 1, 2026, through Dec. 31, 2027, and 387 in other states, though the total could change as staff pursue redeployment opportunities.
All entries for: Biologic
March 31, 2026
Novartis/NJ
Layoffs
East Hanover, NJ
50,001+ employees
Novartis is laying off 114 employees at its East Hanover, New Jersey site, with terminations running from June 26 through Nov. 27, continuing a pattern of workforce reductions at the location over the past year.
Disease Area: Oncology, Rare Disease
Drug Type: Biologic, Small Molecule
March 26, 2026
Takeda
Layoffs
Cambridge, MA
50,001+ employees
Takeda has announced a significant restructuring to streamline corporate functions and generate more than $1.25 billion in savings by fiscal year 2028, though the full workforce impact has not yet been disclosed.
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
March 20, 2026
BiomX
Layoffs
Tel Aviv, Israel
51-200 employees
BiomX laid off a significant portion of its staff in December following the discontinuation of its Phase 2b multi-phage cocktail BX004 for cystic fibrosis, after an external data monitoring committee identified unexpectedly high rates of adverse events.
Disease Area: Respiratory Diseases
Drug Type: Biologic
March 19, 2026
Larimar Therapeutics
Neutral Outlook
Bala Cynwyd, PA
51-200 employees
Since that time, there have been multiple healthcare reform measures, including the Inflation Reduction Act of 2022 (“IRA”) which, among other things, allows HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D. The negotiated price may not exceed a statutory ceiling price. Only high-expenditure single-source biologics that have been approved for at least 11 years (7 years for small molecule drugs) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year.
Disease Area: Neurological Diseases, Rare Diseases
Drug Type: Biologic
March 18, 2026
ProKidney Corp.
Neutral Outlook
Winston-Salem, NC
51-200 employees
However, the IRA’s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.
Disease Area: Endocrinology
Drug Type: Biologic
March 18, 2026
Estrella Immunopharma
Neutral Outlook
Emeryville, CA
1-50 employees
Since its enactment, there have been judicial, congressional and executive branch challenges and amendments to certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of pocket cost and through a newly established manufacturer discount program.
Disease Area: Immune Diseases, Oncology
Drug Type: Biologic
March 18, 2026
4D Molecular Therapeutics
Neutral Outlook
Emeryville, CA
201-500 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Ophthalmology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic
March 18, 2026
Marker Therapeutics
Neutral Outlook
Houston, TX
1-50 employees
Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.
Disease Area: Hematology, Oncology
Drug Type: Biologic
March 17, 2026
Indaptus Therapeutics
Neutral Outlook
New York, NY
1-50 employees
Most recently, the Inflation Reduction Act of 2022, or IRA, included a number of significant drug pricing reforms, which include the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services, or HHS (beginning in 2026) that requires manufacturers to charge a negotiated “maximum fair price” for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers under Medicare Parts B and D to penalize price increases that outpace inflation (first due in 2023), and a redesign of the Part D benefit, as part of which manufacturers are required to provide discounts on Part D drugs (beginning in 2025).
Disease Area: Immune Diseases, Oncology
Drug Type: Biologic